Urovant Sciences Ltd. (UROV): Price and Financial Metrics
UROV Price/Volume Stats
| Current price | $16.24 | 52-week high | $16.26 |
| Prev. close | $16.23 | 52-week low | $7.15 |
| Day low | $16.21 | Volume | 1,739,000 |
| Day high | $16.24 | Avg. volume | 114,469 |
| 50-day MA | $16.19 | Dividend yield | N/A |
| 200-day MA | $12.24 | Market Cap | 531.75M |
UROV Stock Price Chart Interactive Chart >
Urovant Sciences Ltd. (UROV) Company Bio
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. The company was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
UROV Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | 18.71% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | 0.00% |
| 2020 | 4.00% |
| 2019 | 135.36% |
Loading social stream, please wait...